2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Breast
1
Conditions
Keratosis, Actinic
12
Head and Neck Neoplasms
3
Condylomata Acuminata
3
Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Exanthema
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Wounds and Injuries
1
Warts
1
Virus Diseases
1
Usual Type Vulval Intraepithelial Neoplasia (uVIN)
1
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Squamous Intraepithelial Lesions
1
Skin Neoplasms
1
Sexually Transmitted Diseases
1
Radiodermatitis
1
Parapsoriasis
1
Papillomavirus Infections
1
Non-Muscle Invasive Bladder Neoplasms
1
Non-Melanoma Skin Cancers
1
Non-Melanoma Skin Cancer (NMSC)
1
Lymphoma, Follicular
1
Keratosis, Seborrheic
1
Hypogonadism
1
Hemangioma, Cavernous
1
Interventions
Morphine
16
Oxycodone
14
Fentanyl
10
Methadone
7
nabiximols
5
Lidocaine
5
Acetaminophen
5
resiniferatoxin
4
Hydromorphone
4
Ethanol
4
Acupuncture Therapy
4
Transcutaneous Electric Nerve Stimulation
3
Buprenorphine
3
Transcranial Direct Current Stimulation
2
Tapentadol
2
Surveys and Questionnaires
2
Standard of Care
2
Sodium Bicarbonate
2
Radiosurgery
2
Radiofrequency Ablation
2
Pharmaceutical Services
2
Naloxone
2
Ketamine
2
Electroacupuncture
2
Dronabinol
2
Control Groups
2
Analgesics, Opioid
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
tanezumab
1
rofecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cancer Pain
×
Gels
×
Clear all
NCT05800834
2023-09-28
MorphineGEL
Instituto Nacional de Cancer, Brazil
Phase 2
Unknown
106 enrolled